MBX Biosciences reports Q4 EPS (47c), consensus (59c)

“MBX is entering 2025 with strong momentum following significant and transformational progress in 2024,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences (MBX). “We are poised to deliver Phase 2 clinical data on our lead program in hypoparathyroidism, canvuparatide, with topline results from our Avail trial anticipated in the third quarter of 2025. Additionally, we are well-positioned to enter the clinic with our first obesity candidate later this year, pending clearance of our investigational new drug application with the U.S. Food and Drug Administration. Finally, we look forward to initiating a Phase 2 trial evaluating MBX 1416 in post-bariatric hypoglycemia patients in the second half of 2025.”